Results 191 to 200 of about 6,459 (257)

Semaglutide and tirzepatide for obesity: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council. [PDF]

J Manag Care Spec Pharm
Agboola F, Fahim SM, Lin GA, Lee W, Richardson M, Rind D.   +5 more
europepmc   +1 more source

The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.
ABSTRACT Aims The use of pharmacotherapies with weight loss properties for the management of obesity and chronic disease are now routinely prescribed. We investigated the evidence from randomised‐controlled trials for the effects on lean body mass of glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose co‐transporter‐2 inhibitors ...
Rishi Jobanputra, Jack A. Sargeant, Tatiana Plekhanova, Emily James, Abdullah Almaqhawi, David R. Webb, Melanie J. Davies, Thomas Yates   +7 more
wiley   +1 more source

ICER report demonstrates both the value and challenges in financing of weight loss medications. [PDF]

J Manag Care Spec Pharm
Ramachandran S, Urick B, Thomas T.
europepmc   +1 more source

Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression. [PDF]

Medicina (Kaunas)
Abenavoli L, Loricchio AG, Lopez I, Morano D, Ismaiel A, Dumitrascu DL, Luzza F.   +6 more
europepmc   +1 more source

Long‐Term Glycemic and Metabolic Profiles Observed During Imeglimin Therapy in Japanese Patients With Type 2 Diabetes Mellitus

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
In a real‐world setting, 12‐month imeglimin therapy in Japanese patients with type 2 diabetes provided sustained glycemic improvements and enhanced endogenous insulin secretion. Importantly, these durable metabolic benefits were achieved without requiring an increase in overall glucose‐lowering treatment intensity.
Yohei Fujita, Shuji Suganami, Yuka Morita, Toshio Matsui, Masahisa Hata, Masahiro Hatazaki   +5 more
wiley   +1 more source

Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™. [PDF]

Adv Ther
Gibble TH, Leith A, Harrison L, Gerber C, Raikar SK, Ashok G, Artime E.   +6 more
europepmc   +1 more source

Could Incretin‐Based Weight Loss Unmask a Modifiable Nociplastic Pain Phenotype? A Rheumatological Reading of SURMOUNT‐5

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6475-6477, August 2026.
Jacopo Ciaffi, Roberto Caporali, Francesco Ursini   +2 more
wiley   +1 more source

Prevalence of Pre‐Clinical Obesity Among US Adults Receiving Medical and Surgical Obesity Treatment

Obesity, Volume 34, Issue 7, Page 1493-1501, July 2026.
ABSTRACT Objective We sought to determine how the proportion of adults historically receiving obesity interventions would be classified under the recently proposed “pre‐clinical” and “clinical” obesity classifications and the impact of this change on safety and outcomes.
Jason M. Samuels, Emma Holler, Matthew D. Spann, C. Joe Northup, Tarik K. Yuce   +4 more
wiley   +1 more source

Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes. [PDF]

Dermatol Ther (Heidelb)
Piraccini BM, Vañó-Galván S, Blume-Peytavi U, Ribet V, Mengeaud V.   +4 more
europepmc   +1 more source